Galena Biopharma (GALE) Tops Q3 EPS by 6c

Galena Biopharma (NASDAQ: GALE) reported Q3 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $2.66 million.

For earnings history and earnings-related data on Galena Biopharma (GALE) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Nlight (LASR) Reiterated at Buy by Stifel: Sell-off is a 'Buying Opportunity'
• Advance Auto Parts falls on revenue miss, weak guidance